The French Competition Authority analyses parallel behaviour as proof of a concerted practice and excessive pricing by a dominant company, in the context of a price-regulated sector (Ethicon / Tyco Healthcare France / Syndicat national des industries technologies médicales)

I. Introduction The main interest of this decision of the French Competition Authority (hereafter « the Competition Authority ») lies in its analysis of parallel behaviour as proof of a concerted practice, on the one hand, and excessive pricing by a dominant company, on the other, in the context of a price-regulated sector (healthcare equipment). Even if perhaps of lesser interest, it can also be noted for its specifications regarding a professional association's purposes in light of competition law. II. Background The facts giving rise to this decision are simple: in the sector of medical implants, two firms - Tyco Healthcare France and Ethicon SAS - represented respectively 55 and 40% of sales. Until 1996, there were no regulatory constraints on their product prices, which were

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

Citation

Emmanuel Dieny, The French Competition Authority analyses parallel behaviour as proof of a concerted practice and excessive pricing by a dominant company, in the context of a price-regulated sector (Ethicon / Tyco Healthcare France / Syndicat national des industries technologies médicales), 17 décembre 2009, e-Competitions December 2009, Art. N° 32053

Visites 1243

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues